Views & Analysis Staying on the cutting edge of oncology advances Rapidly-changing treatment landscapes in diseases like lung cancer pose challenges for medical education providers, who need to be more adaptable than ever.
News Gilead to buy immuno-oncology firm Forty Seven for $4.9bn Gilead is to buy immuno-oncology firm Forty Seven for $4.9 billion, adding an antibody targeting several blood cancers to its research pipeline.
Events Partner Content PREDiCT: Imaging Modalities for Oncology Drug Development Guiding Your Strategic Approach of Multimodal Imaging
News GSK begins cancer cell therapy tie-up with Immatics Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.